PAG
VRTX icon

Private Advisor Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Private Advisor Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500
Closed -$1.74K – 2527
2023
Q3 		$1.74K Buy
+500
New +$175K ﹤0.01% 2238

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Private Advisor Group's VRTX Position: Q1 2026 in Review

Private Advisor Group reduced its Vertex Pharmaceuticals (VRTX) stake by 3% in Q1 2026, selling an estimated $122K and leaving 8,433 shares worth $3.77M. The position accounts for 0.02% of the portfolio, ranked #761.

Private Advisor Group first reported a position in VRTX in Q4 2014 and has held it in 46 quarters since. The position peaked at $8.95M in Q2 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Private Advisor Group held 8,433 shares of Vertex Pharmaceuticals worth $3.77M as of Q1 2026.
  • Private Advisor Group sold 261 Vertex Pharmaceuticals shares in Q1 2026, an estimated $122K.
  • Vertex Pharmaceuticals made up 0.02% of Private Advisor Group's portfolio in Q1 2026, its #761 holding.
  • Private Advisor Group first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • Private Advisor Group's Vertex Pharmaceuticals position peaked at $8.95M in Q2 2022.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.